Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

Fondation Ophtalmologique Adolphe de Rothschild3 sites in 1 country37 target enrollmentJanuary 2014

ConditionsPolypoidal Choroidal Vasculopathy

InterventionsIntravitreal aflibercept

DrugsIntravitreal aflibercept

Overview

Phase: Not Applicable
Intervention: Intravitreal aflibercept
Conditions: Polypoidal Choroidal Vasculopathy
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Enrollment: 37
Locations: 3
Primary Endpoint: Evolution of the best corrected visual acuity (BCVA) measured on the EDTRS scale, between pre-injection and 28 weeks after injection
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal vasculature, that is often regarded as a sub-type of age-related macular degeneration (AMD). However, PCV response to anti-vascular agents differs from the response of typical AMD.

This study aims at describing the evolution of the best corrected visual acuity (BCVA) in PCV patients, 28 weeks after they receive one injection of intravitreal aflibercept (2mg).

Registry

clinicaltrials.gov

Start Date

January 2014

End Date

August 31, 2017

Last Updated

8 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Active polypoidal choroidal vasculopathy,
•Visual acuity superior to 1/10 (20/200) and inferior to 6,25/10 (20/32)
•Age above 45
•No prior intravitreal treatment, or no response to prior treatment by 3 injections of ranibizumab, or disease recurrence after more than 3 months of stability
•Intravitreal injection of aflibercept is indicated by current clinical recommendations